FDA Social Media Warning Letter: A Fragmented Approach to a Comprehensive Problem

In recent years, the promotion and marketing of pharmaceutical products has been affected not only by the advent of direct-to-consumer advertising, but also by the proliferation of social networking and other online media tools such as blog posts, message boards, chat rooms, Facebook, and Twitter. Pharmaceutical companies have never before had such a direct link to users and potential users of its products. Equally important, these consumers have the means to communicate with each other about their experiences. The U.S. Food and Drug Administration’s advertising and promotion regulations barely scratch the surface of the issues implicated by these new forms of communication, and despite industry pleas, the Agency has yet to issue formal guidance in this area.

Click here to read the full publication →